| Name | Title | Contact Details |
|---|
Patient Care Technology Systems is a Mission Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gunn Plastic Surgery Center is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cherry Health is an independent, non-profit Federally Qualified Health Center (FQHC) with a primary focus of providing high quality health services to those who have little or no access to health care, regardless of income or insurance status. Services provided by Cherry Health include primary care, women`s health, pediatrics, dental, vision, behavioral health, mental health, correctional health, five school based health centers and employee assistance for employers. Cherry Health provides services to all individuals, regardless of their ability to pay. A sliding fee payment scale based on income and family size is available to those without insurance. Medicaid and Healthy Michigan are accepted, as are many other insurances. Established in 1988, Cherry Health is the largest FQHC in the state of Michigan serving Barry, Eaton, Kent, Montcalm and Wayne counties at more than 20 locations, 14 of which are primary care Federally Qualified Health Center sites, Cherry Health employs over 800 employees and a network of over 60 physicians and mid-level providers specializing in primary care/family medicine, pediatrics, internal medicine, obstetrics/gynecology, optometry and psychiatry. Additionally, Cherry Health runs a school linked program active in 70 public schools offering both vision and dental care.
Interpore Cross is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.